Dexmedetomidine and Subarachnoid Haemorrhage

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

November 30, 2016

Study Completion Date

December 30, 2016

Conditions
Subarachnoid HemorrhageAneurysm
Interventions
DRUG

Dexmedetomidine infusion

"Both static and dynamic autoregulation are assessed first during propofol infusion, before commencement of dexmedetomidine infusion. Dexmedetomidine infusion is commenced with a dose of 0.7 μg/kg/h and propofol infusion is stopped concomitantly. After 2 hours dexmedetomidine infusion, the static and dynamic autoregulation are assessed. If there are no signs of worsening of autoregulation, then the dexmedetomidine infusion is increased to 1 μg/kg/h and after 2 hours the static and dynamic autoregulation are assessed again. However, if autoregulation worsens during dexmedetomidine infusion, it will be stopped and further testing with dexmedetomidine will not be carried out. If autoregulation does not worsen with the 1 μg/kg/h dose then the dose will be increased to 1.4 μg/kg/h. After 2 hours infusion the dynamic and static autoregulation are assessed again.~Blood samples for determining dexmedetomidine plasma concentration are collected alongside with the autoregulation assessments"

Trial Locations (1)

20520

Turku University Hospital, Turku

All Listed Sponsors
collaborator

Orion Corporation, Orion Pharma

INDUSTRY

lead

Turku University Hospital

OTHER_GOV

NCT01664520 - Dexmedetomidine and Subarachnoid Haemorrhage | Biotech Hunter | Biotech Hunter